One Farrer Hotel

2025 年 07 月 15 日 8:30 上午 - 2025 年 07 月 16 日 5:30 下午

1 Farrer Park Station Road, Singapore 217562, Singapore

DIA Singapore Annual Meeting 2025

Charting the Future: Navigating the Evolving Healthcare Landscape and Trends in Asia

概览

Charting the Future: Navigating the Evolving Healthcare Landscape and Trends in Asia Drug development and healthcare innovation in Asia is being rapidly reshaped by advancements in digital technologies, e.g. Artificial Intelligence.
(AI), cloud platforms, changing regulatory guidelines, and innovative clinical trial methodologies. These transformations are accelerating drug development, streamlining regulatory review processes, and enhancing patient engagement. To harness the full potential of these emerging opportunities and foster a dynamic and robust regulatory and clinical trial ecosystem, close collaborations among regulators, academia, patients, and industry are necessary..
The DIA Singapore Annual Meeting 2025 invites all stakeholders to share and review the evolving healthcare landscape challenges faced and lessons learned, and to identify future trends in the clinical research and regulatory environment in Asia. In-depth discussions will focus on key topics such as: Join us at DIA Singapore 2025 to navigate these transformative changes and shape the future of healthcare in Asia.

Click Here to View the Flyer

精选主题

  • Role of AI and digital toolsin clinical trials, regulatory affairs and pharmacovigilance
  • Optimizing the implementation of regulatry pathway
  • Real-World Data (RWD) and digital innovations to enhance regulatory decision-making
  • Multi-Regional Clinical Trials and simultaneous global drug developmet
  • Decentralized Clinical Trials (DCT) and AI implementation in clinical trials

学习目标

Participants will enhance their understanding of key global regulatory developments from recent years, aiding in anticipating future changes and their impact in Asia, while broadening their perspectives.

This knowledge can be applied within their organizations to inform strategies for clinical development and regulatory submissions.

 

项目委员会

  • Finny  Liu, MSc, RPh
    Finny Liu, MSc, RPh APAC Regional Regulatory Policy Lead
    Roche, Singapore
  • Helene  Sou, MSc, RAC
    Helene Sou, MSc, RAC Global Regulatory Policy and Innovation
    Takeda Pharmaceutical Company Limited., Singapore
  • Sandy  Chan
    Sandy Chan Associate Director, Regulatory Policy & Intelligence Lead- Asia Pacific
    Johnson & Johnson, Singapore
  • Martin  Lim, MBA, MS
    Martin Lim, MBA, MS Co-Founder and CEO
    ONWARD Health Research, Singapore
  • Thean Soo  Lo
    Thean Soo Lo
    Regulatory Affairs Management Consultant, Singapore
  • Edana  Loke
    Edana Loke Assoc Dir - Asia, Australia, Africa, Middle East, Area & Affiliate Strategy
    AbbVie Pte Ltd, Singapore
  • Karin  Markgraf
    Karin Markgraf Head Regulatory Affairs, APAC
    Merck Pte Ltd, Singapore
  • Audrey  Ooi, MSc
    Audrey Ooi, MSc Head- Business Development
    Clinical Research Malaysia, Malaysia

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。